Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026)

Rigel Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $89.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 34.31% year-over-year to $89.5 million in Q1 2026; TTM through Mar 2026 was $89.5 million, a 34.31% increase from a year earlier, with the FY2025 full-year figure at $99.2 million, up 56.77% from the prior year.
• Total Current Liabilities declined to $89.5 million in Q1 2026 per RIGL's latest filing, from $99.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $99.2 million in Q4 2025 and bottomed at $44.0 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $59.2 million (2022), against an average of $64.9 million.
• Across the five-year window, Total Current Liabilities retreated 23.14% in 2023 and soared 73.81% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $65.2 million in 2022, then declined by 18.32% to $53.3 million in 2023, then grew by 18.83% to $63.3 million in 2024, then jumped by 56.77% to $99.2 million in 2025, then decreased by 9.82% to $89.5 million in 2026.
• Per Business Quant, the three latest RIGL Total Current Liabilities figures stand at $89.5 million (Q1 2026), $99.2 million (Q4 2025), and $94.4 million (Q3 2025).